Company Monitoring Page for JNJ

latest headlines for company on cafepharma

J&J Reports Positive Data in Impella ECP Trial
Medical Devices and Diagnostics Industry
Mon, 10/28/24 - 06:18 pm
Tags:
Abiomed, JNJ, Johnson & Johnson MedTech, Imprella ECP, medtehc
Medtronic Earns Another PFA Approval, Is J&J Next in Line?
Medical Devices and Diagnostics Industry
Sun, 10/27/24 - 07:35 pm
Tags:
Medtech, pulsed field ablation, Medtronic, Boston Scientific, JNJ
J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups
Fierce Pharma
Fri, 10/25/24 - 11:43 am
Tags:
JNJ, Eli Lilly, Tremfya, immunology, plaque psoriasis, Ebglyss, atopic dermatits
J&J’s comeback kid Spravato heads for blockbuster status
Pharma Voice
Fri, 10/25/24 - 11:13 am
Tags:
JNJ, esketamine, Spravato
Activist investor Starboard sets its sights on J&J spinout Kenvue
Fierce Pharma
Mon, 10/21/24 - 11:38 pm
Tags:
Starboard, Pfizer, JNJ, Kenvue, activist investors
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
BioPharma Dive
Wed, 10/16/24 - 05:19 pm
Tags:
JNJ, Carvykti, Tremfya, Stelara, patents
J&J makes surgical robotic moves with Ottava FDA IDE application
Clinical Trials Arena
Wed, 10/16/24 - 12:22 pm
Tags:
Medtech, JNJ, IDE, FDA, robotic surgery, Ottava
J&J reports Q3 sales surge of 5.2% despite EPS decline due to M&A activity
Medical Marketing and Media
Tue, 10/15/24 - 11:30 am
Tags:
JNJ, earnings, M&A
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
Fierce Pharma
Tue, 10/15/24 - 10:15 am
Tags:
Eli Lilly, Crohn's Disease, Omvoh, clinical trials, JNJ, Stelara
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Fierce Biotech
Tue, 10/15/24 - 10:10 am
Tags:
JNJ, nipocalimab, myasthenia gravis, adolescents
J&J discontinues late-stage study for bladder cancer drug
Reuters
Mon, 10/7/24 - 10:01 pm
Tags:
JNJ, bladder cancer, clinical trials, TAR-200
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
Fierce Pharma
Wed, 10/2/24 - 09:50 pm
Tags:
JNJ, Erleada, prostate cancer, Astellas, Pfizer, Xtandi
High-flying Eli Lilly pushes more chips forward with $4.5B 'Medicine Foundry' project
Fierce Pharma
Wed, 10/2/24 - 11:27 am
Tags:
Eli Lilly, JNJ, medicine foundry, drug manufacturing
Big Pharma's layoff wave in New Jersey rolls on with hundreds of J&J cuts, 57 at Bayer
Fierce Pharma
Tue, 10/1/24 - 10:19 pm
Tags:
Big Pharma, layoffs, JNJ, Bayer, New Jersey
As urged by the AHA and others, J&J tells HRSA it is abandoning proposed 340B rebate plan
American Hospital Association
Mon, 09/30/24 - 09:00 pm
Tags:
JNJ, 340B, HRSA
After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data
Fierce Pharma
Mon, 09/30/24 - 09:30 am
Tags:
Sanofi, JNJ, Sarclisa, Darzalex Faspro, Multiple Myeloma, FDA
J&J to shutter cardiovascular, metabolic drug unit
Seeking Alpha
Thu, 09/26/24 - 03:15 pm
Tags:
JNJ, layoffs, restructuring, cardiovascular disease, metabolic diseases
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
Yahoo/Zacks.com
Mon, 09/23/24 - 10:25 pm
Tags:
JNJ, legal, bankruptcy
J&J hopes 3rd time's the charm for Texas two-step strategy as it lifts talc settlement offer to $8B
Fierce Pharma
Mon, 09/23/24 - 09:51 am
Tags:
JNJ, legal
At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
Pharma Voice
Thu, 09/19/24 - 09:22 am
Tags:
JNJ, R&D, oncology

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.